61 results
8-K
EX-99.1
PULM
Pulmatrix, Inc.
28 Mar 24
Pulmatrix Announces Year-End and Q4 2023 Financial Results and Provides Corporate Update
9:05am
ongoing and planned clinical trials; the geographic, social and economic impact of COVID-19 on the Company’s ability to conduct its business and raise
8-K
EX-99.1
PULM
Pulmatrix, Inc.
8 Jan 24
Entry into a Material Definitive Agreement
9:00am
and allocate our cash on-hand most efficiently, the geographic, social and economic impact of COVID-19 on the Company’s ability to conduct its business
8-K
EX-99.1
PULM
Pulmatrix, Inc.
9 Nov 23
Pulmatrix Announces Third Quarter 2023 Financial Results and Provides Corporate Update
9:05am
of the novel coronavirus (COVID-19) endemic on the Company’s ongoing and planned clinical trials; the geographic, social and economic impact of COVID-19
8-K
EX-99.1
PULM
Pulmatrix, Inc.
10 Aug 23
Pulmatrix Announces Second Quarter 2023 Financial Results and Provides Corporate Update
9:05am
; the geographic, social and economic impact of COVID-19 on the Company’s ability to conduct its business and raise capital in the future when needed; delays
8-K
EX-99.1
PULM
Pulmatrix, Inc.
11 Jul 23
Pulmatrix Announces Submission of IND Application to FDA to Initiate a Phase 2 Trial of Investigational Drug PUR3100 to Treat Acute Migraine
9:05am
; the geographic, social and economic impact of COVID-19 on the Company’s ability to conduct its business and raise capital in the future when needed; delays
8-K
EX-99.1
n1npuh1cepj3vt
12 May 23
Pulmatrix Announces First Quarter 2023 Financial Results and Provides Corporate Update
9:05am
8-K
EX-99.1
tbst6nq8bro6wi4hku7z
30 Mar 23
Pulmatrix Announces Year-End and Q4 Financial 2022 Results and Provides Corporate Update
9:05am
8-K
EX-99.1
l04cq17
14 Nov 22
Pulmatrix Announces Third Quarter 2022 Financial Results and Provides Corporate Update
6:17am
8-K
EX-99.1
xtwz5g3v2
26 Sep 22
Pulmatrix Announces Patient Dosing Completed for its Novel Inhaled Therapy PUR3100 for Acute Migraine
9:00am
8-K
EX-99.1
2661z0ri7tvis
10 Aug 22
Pulmatrix Announces Second Quarter 2022 Financial Results and Provides Corporate Update
9:15am
8-K
EX-99.1
uv7wx3b
12 Jul 22
Pulmatrix Announces First Subject Dosed in Phase 1 Study of PUR3100 for Acute Migraine
9:00am
8-K
EX-99.1
1jn 6u4vv
12 May 22
Pulmatrix Announces First Quarter 2022 Financial Results and Provides Corporate Update
9:15am
8-K
EX-10.1
s0szqf kvbf1hwbeg
15 Apr 22
Departure of Directors or Certain Officers
4:11pm
8-K
EX-99.1
ccx5gf6y73ntf1f6
29 Mar 22
Pulmatrix Announces Year-End and Q4 Financial 2021 Results and Provides Corporate Update
9:15am
8-K
EX-99.1
gkokaw5
21 Mar 22
Pulmatrix Announces Positive Top-Line Data Evaluating PUR1800 in Patients with Stable COPD
8:15am
8-K
EX-99.1
29x1kc3
17 Mar 22
Other Events
4:15pm
8-K
EX-99.1
gk9d 2ph8
4 Mar 22
Pulmatrix Announces Expansion of Executive Leadership Team to Progress Clinical Pipeline
8:00am
8-K
EX-99.1
yqyuhdv6l92 zr
24 Feb 22
Pulmatrix, Inc. Announces 1-for-20 Reverse Stock Split
4:10pm
DEFA14A
aeets79z h90
1 Feb 22
Additional proxy soliciting materials
9:10am
DEFA14A
EX-99.1
izts hta8qh
17 Dec 21
Additional proxy soliciting materials
5:03pm